OS-01 Peptide: Anti-Aging Eye Drops That Reverse Biological Age

What Is OS-01?

OS-01 is the peptide-based active ingredient in Visomitin eye drops, a product developed from decades of research into mitochondria-targeted antioxidants. The compound is based on SkQ1 (plastoquinonyl-decyl-triphenylphosphonium), a molecule designed by Russian biochemist Vladimir Skulachev to specifically accumulate in mitochondria and neutralize reactive oxygen species (ROS) at their primary source of production.

What made OS-01 a topic of intense interest in the longevity community was a 2023 study by Yuvan Research demonstrating that topical application of OS-01 eye drops reversed epigenetic age in human eye tissue — essentially making the molecular age of eye cells younger according to DNA methylation clocks. This was one of the first demonstrations of biological age reversal using a topical peptide-based intervention in humans.

If you are new to peptides and their role in anti-aging research, our What Are Peptides? overview and Anti-Aging goal page provide foundational context.

Mitochondrial Theory of Aging and Eye Health

To understand OS-01, you need to understand why mitochondria matter for aging — and why the eye is particularly vulnerable:

Mitochondrial ROS and Aging. Mitochondria produce energy (ATP) through oxidative phosphorylation, but this process inevitably generates reactive oxygen species as byproducts. Over time, accumulated ROS damage mitochondrial DNA, proteins, and lipid membranes, creating a vicious cycle: damaged mitochondria produce more ROS, which causes more damage. This mitochondrial theory of aging is one of the most well-supported frameworks in gerontology.

Why the Eye Is Vulnerable. The eye is uniquely susceptible to mitochondrial oxidative damage for several reasons: the retina has one of the highest metabolic rates of any tissue in the body (requiring enormous mitochondrial output), the lens and retina are constantly exposed to light (which generates additional ROS through photochemical reactions), and the cornea and lens have limited antioxidant renewal capacity. Age-related eye diseases — including cataracts, macular degeneration, and glaucoma — all have strong mitochondrial ROS components.

Skulachev's Solution. Vladimir Skulachev spent decades developing molecules that could be targeted specifically to mitochondria. The key innovation was conjugating an antioxidant (plastoquinone, a natural electron carrier found in chloroplasts) with a lipophilic cation (triphenylphosphonium, TPP+). The positive charge of TPP+ is attracted to the negative membrane potential of mitochondria, causing the molecule to accumulate inside mitochondria at concentrations 100-1,000 times higher than in the cytoplasm.

SkQ1 Mechanism: How OS-01 Targets Mitochondrial Aging

SkQ1 (the active molecule in OS-01 eye drops) works through several interconnected mechanisms:

1. Targeted ROS Neutralization. SkQ1 accumulates in the inner mitochondrial membrane, precisely where ROS are generated during electron transport. It neutralizes superoxide and lipid peroxyl radicals before they can damage mitochondrial DNA and membranes. Unlike systemic antioxidants that are distributed throughout the body at low concentrations, SkQ1's targeting mechanism ensures effective concentrations at the site where damage occurs.

2. Mitochondrial Membrane Protection. Cardiolipin, a phospholipid unique to mitochondrial membranes, is particularly vulnerable to oxidative damage. Cardiolipin oxidation disrupts the electron transport chain and triggers apoptotic signaling. SkQ1 protects cardiolipin from peroxidation, preserving mitochondrial membrane integrity and function.

3. Anti-Apoptotic Effect. By preventing mitochondrial membrane permeabilization, SkQ1 inhibits the release of cytochrome c — a key trigger of the intrinsic apoptosis pathway. This prevents the programmed death of cells that are damaged but potentially salvageable, preserving tissue function.

4. Epigenetic Age Reversal. The most striking finding from the Yuvan Research study was that OS-01 treatment reversed DNA methylation age in eye tissue. DNA methylation clocks (developed by Steve Horvath and others) measure biological age by assessing methylation patterns at specific CpG sites. The observation that a topical treatment can reverse these patterns suggests that reducing mitochondrial ROS may be sufficient to reverse some age-related epigenetic changes.

Clinical Research and Trial Data

OS-01/Visomitin has been studied in several clinical settings:

Dry Eye Disease. Visomitin received approval in Russia in 2011 for dry eye syndrome. Clinical trials demonstrated improvements in tear film stability, reduced corneal staining (a marker of surface damage), and improved subjective comfort scores compared to placebo. The effect was attributed to reduced oxidative damage to corneal and conjunctival epithelial cells.

Cataracts. Animal studies showed that SkQ1 eye drops prevented cataract development in multiple models (senescence-accelerated mice, UV-induced cataracts). In a small human pilot study, SkQ1 drops were associated with modest improvements in early-stage cataract progression, though large-scale confirmation is pending.

Age-Related Macular Degeneration (AMD). Preclinical data suggests SkQ1 protects retinal pigment epithelial (RPE) cells from oxidative damage — RPE dysfunction is a central driver of AMD. Clinical trials in AMD are ongoing but no definitive human data has been published.

Epigenetic Age Reversal (Yuvan Study). The study that generated the most attention evaluated OS-01 eye drops in human subjects and measured biological age using DNA methylation clocks. The results showed a statistically significant reversal of epigenetic age in treated eyes compared to controls. While the study was relatively small and the long-term implications require further investigation, the finding represented a proof of concept that topical mitochondrial-targeted antioxidants can influence biological aging markers. For context on other anti-aging peptides like Epitalon (telomerase activation) and SS-31 (another mitochondrial peptide), see our Anti-Aging Stack.

Dosage and Application

OS-01 is applied topically as eye drops, which distinguishes it from most peptides that require injection:

Application Technique. Standard eye drop application: tilt head back, pull down lower eyelid to form a pocket, instill one drop, close eyes gently for 1-2 minutes. Avoid touching the dropper tip to the eye or any surface. If using multiple eye medications, wait at least 5 minutes between applications.

No Injection Required. Unlike most peptides covered on this site, OS-01 is applied topically. The cornea is one of the few tissues where topical peptide delivery is effective due to its accessibility and the specialized formulation of Visomitin. This is not applicable to other peptides — topical application of most peptides (BPC-157, TB-500, GH secretagogues) does not achieve meaningful systemic levels. For injectable peptide guidance, see our injection guide.

Safety Profile

SkQ1/Visomitin has demonstrated a favorable safety profile across clinical studies:

• Common: mild transient stinging upon application (similar to most eye drops), temporary blurred vision immediately after instillation
• Uncommon: eye redness, mild allergic conjunctival reaction
• Serious adverse events: none reported in published clinical trials or post-marketing surveillance from Russian approval

Systemic Safety. Because OS-01 is applied topically to the eye, systemic absorption is minimal. The doses reaching systemic circulation are far below those used in animal systemic SkQ1 studies, which showed favorable safety profiles even at higher systemic doses. This is a significant advantage over systemic antioxidant therapies.

For general peptide safety principles, see our Are Peptides Safe? guide.

OS-01 in the Anti-Aging Peptide Landscape

OS-01 fits within a broader category of anti-aging peptide strategies, each targeting different hallmarks of aging:

The Anti-Aging Stack combines Epitalon, GHK-Cu, and SS-31 — addressing telomeres, gene expression, and mitochondria simultaneously. OS-01 complements this approach by targeting mitochondrial aging specifically in eye tissue, which cannot be reached effectively by systemically administered compounds. For a deep dive into GHK-Cu's skin and tissue remodeling research, see our GHK-Cu research review.

Limitations and Honest Assessment

Several important caveats should be considered:

• Epigenetic age reversal needs replication. The Yuvan Research study was groundbreaking but relatively small. Independent replication in larger cohorts is needed to confirm the epigenetic age reversal finding and determine its clinical significance.
• Functional outcomes unclear. Reversing epigenetic age is exciting, but the critical question is whether this translates to meaningful functional improvements — better visual acuity, reduced risk of age-related eye diseases, or preservation of retinal function. Long-term functional outcome data is not yet available.
• Limited to eye tissue. OS-01 eye drops only affect ocular tissue. The epigenetic age reversal was demonstrated in eyes, not systemically. Those seeking whole-body anti-aging strategies need additional approaches.
• Availability. Visomitin is approved in Russia but not in the US, EU, or most other markets. Access outside Russia requires importing, which raises quality and regulatory concerns.
• Commercial formulation matters. The specific formulation, concentration, and excipients in OS-01 eye drops affect delivery and efficacy. Compounded or alternative SkQ1 products may not match the studied formulation.

The Bottom Line on OS-01

OS-01 represents a genuinely innovative approach to anti-aging — targeting mitochondrial ROS at the source in one of the body's most vulnerable tissues. The epigenetic age reversal finding, while preliminary, is one of the most striking results in longevity research involving a topical intervention. Combined with clinical approval for dry eye disease in Russia and favorable safety data, OS-01 has a stronger evidence foundation than many compounds in the anti-aging peptide space.

The limitations are real: the landmark epigenetic study needs independent replication, functional outcome data is limited, and availability outside Russia is restricted. But for those building a comprehensive anti-aging strategy, OS-01 addresses mitochondrial aging in eye tissue — a target that systemically administered peptides cannot easily reach. It pairs conceptually with SS-31 (systemic mitochondrial protection), Epitalon (telomere support), and GHK-Cu (gene expression and tissue remodeling) for a multi-hallmark approach to biological aging.